BMS-986504 is showing promising and sustained anti-cancer activity in patients with non-small cell lung cancer (NSCLC) whose tumors have lost a gene called MTAP, according to data released September 8, 2025. The experimental therapy demonstrated durable responses not only in MTAP-deleted tumors but also in those harboring EGFR and ALK genetic alterations-two common drivers of lung cancer-offering a potential new treatment avenue for a arduous-to-treat population.
This development is meaningful becuase MTAP deletion is present in approximately 15% of NSCLC cases and is often associated with resistance to standard therapies. The ability of BMS-986504 to overcome this resistance, and to show efficacy across multiple genetic subtypes, suggests it could broaden treatment options for patients with limited alternatives. Further research will focus on larger clinical trials to confirm these findings and determine the optimal use of BMS-986504 in NSCLC treatment regimens.
The research indicates that BMS-986504 elicits durable responses in MTAP-deleted NSCLC, encompassing both EGFR and ALK-positive tumors. The facts was retrieved September 8, 2025, from https://medicalxpress.com/news/2025-09-bms-durable-responses-mtap-deleted.html.This document is subject to copyright.Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
